XKH001 Injection

DRUG5 trials

Sponsors

Beijing Kanova Biopharmaceutical Co., LTD, Zhejiang Kanova Biopharmaceutical Co., LTD

Conditions

AsthmaAsthma PatientsAtopic DermatitisHealthy AdultHealthy Adults

Phase 1

Phase I of XKH001Injection in Healthy Adults

Beijing Kanova Biopharmaceutical Co., LTDHealthy Adults

Start: 2023-03-07End: 2024-12-01Target: 35Updated: 2023-04-12

XKH001 Injection in Healthy Subjects

CompletedNCT05991661

Beijing Kanova Biopharmaceutical Co., LTDAsthma

Start: 2023-05-12End: 2024-03-29Updated: 2026-03-05

A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses

CompletedNCT07070297

Zhejiang Kanova Biopharmaceutical Co., LTDAsthma Patients

Start: 2023-12-26End: 2024-12-20Updated: 2025-07-17

Bridging Study of XKH001 in Healthy Adult Caucasian Participants

Not yet recruitingNCT07757659

Zhejiang Kanova Biopharmaceutical Co., LTDHealthy Adult

Start: 2026-08-01End: 2027-08-01Target: 2Updated: 2026-08-11

Phase 2

Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

Not yet recruitingNCT07054736

Zhejiang Kanova Biopharmaceutical Co., LTDAtopic Dermatitis

Start: 2025-08-31End: 2025-12-01Target: 120Updated: 2025-07-08

Related Papers

First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers

Expert Opinion on Investigational Drugs2025-01-162 citations

Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial

Frontiers in Immunology2024-12-095 citations